Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Saitama International Medical Center, Saitama Medical University, Istituti di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Institute of Peruvian Studies, Liga Nacional Contra el Cáncer, University of Ostrava, Virginia Commonwealth University, Liga Contra el Cancer, Instituto Nacional de Cancerología, Tel Aviv University, Meir Medical Center, Turkish Society of Cardiology, Başkent University, Severance Hospital, Yonsei University, Chelyabinsk Regional Clinical Oncology Center, Alexandra Hospital, McGill University Health Centre, Chiang Mai University, Mackay Memorial Hospital, Masaryk University, University Hospital Brno, Xiangya Hospital Central South University, Central South University, Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Universitari, KU Leuven, Ehime Medical Center, Ehime University Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Virginia